Wednesday opened with an engaging Keynote Presentation by Dr. Christine Mummery from Leiden University on Cardiomyocytes from Human Pluripotent Stem Cells: The New Patient in Safety Pharmacology, Drug Discovery and Disease.
Dr. Mummery discussed and presented data on derivation of heart cells from
Over 400 attendees from across the globe are participating in the SPS Annual meeting this week.
Tuesday opened with an ECG historical talk by Dr. Marc Vos, and the Introduction to Tracks talks by Dr. Jack Reynolds and Dr. Jean-Pierre Valentin (via WebEx!) Their talks covered both the Challenges for
New Postings (as of 9/10/13) AstraZeneca, United Kingdom or United StatesDirector, Safety PharmacologyAstraZeneca, Alderley Park or Cambridge, United KingdomPrincipal Scientist, Safety PharmacologyAstraZeneca, Molndal, SwedenPrincipal Scientist, Safety Pharmacology Current
"On 23 July 2013, the US Food and Drug Administration (FDA), the Health and Environmental Sciences Institute (HESI) and the Cardiac Safety Research Consortium (CSRC) presented a new paradigm for cardiotoxicity testing, with a lofty goal of validating and standardizing the new assays in 2 years' time